Clinical response prediction and improvement for intravesical BCG treatment of superficial bladder cancer| BCG-INMUNO-RESP

View all the clinical researches

Collaboration on clinical research

Clinical response prediction and improvement for intravesical BCG treatment of superficial bladder cancer| BCG-INMUNO-RESP

01/01/2014 - 31/12/2017

Type of research: Prospective pilot study Promoter: IrsiCaixa AIDS Research Institute Principal Investigators: Cecilia Cabrera Participating entities: Fundación Lucha contra el Sida, Servicio de Urología del Hospital Universitario Germans Trias i Pujol

Bladder cancer incidence in Spain is among the highest in the world and a leading cause of deaths from cancer in men. Initial treatment is transurethral resection, although Bacillus Calmette-Guérin (BCG) immunotherapy has proved to be the local treatment that is most effective in reducing recurrence and limiting progression. Since the exact mechanisms and molecular mediators of tumour control after BCG treatment are unknown, there is no reliable predictor of response. An early marker of response would be invaluable, as it would prevent comorbidities, reduce mortality and avoid the cost associated with ineffective treatment. The study aim is to identify predictors of response to BCG treatment and design new therapeutic strategies.

  • Disease: Bladder cancer
  • Sample size: 30
  • CEIC Code: EPA-14- 044

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: